FdaApplication
NDA 213005
Identifiers
- fda_app_no: NDA213005
Properties
| Property | Value |
|---|---|
| applicant_name | LIQUIDIA TECHNOLOGIES INC |
| application_type | NDA |
| approval_date | 2025-05-23 |
Revenue by product
YUTREPIA
| Period | Revenue |
|---|---|
| Q2 2026 | $170.4M |
| Q3 2025 | $51.7M |
| Q1 2025 | $3.1M† |
| Q4 2024 | $2.9M† |
| Q3 2024 | $4.4M† |
| Q2 2024 | $3.7M† |
| Q1 2024 | $3.0M† |
| Q4 2023 | $4.5M† |
| Q3 2023 | $3.7M† |
| Q2 2023 | $4.8M† |
| Q1 2023 | $4.5M† |
| Q4 2022 | $5.4M† |
| Q3 2022 | $3.2M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| YUTREPIA | TREPROSTINIL SODIUM | EQ 0.053MG BASE/INH | POWDER;INHALATION |
| YUTREPIA | TREPROSTINIL SODIUM | EQ 0.0265MG BASE/INH | POWDER;INHALATION |
| YUTREPIA | TREPROSTINIL SODIUM | EQ 0.106MG BASE/INH | POWDER;INHALATION |
| YUTREPIA | TREPROSTINIL SODIUM | EQ 0.0795MG BASE/INH | POWDER;INHALATION |
4 products